Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSSM-001 in Refractory Perianal Fistulizing Crohn's Disease
NCT05407766Phase 1Withdrawn
- Sponsor
- Ossium Health
- Start
- Aug 2022
- Primary completion
- Apr 2024
- Modality
- Mesenchymal Stem Cells
01
Overview
Phase 1, randomised, double-blind trial of ossm-001 in perianal fistula (3 arms), sponsored by Ossium Health. Primary endpoint: OSSM-001 related adverse events as assessed by CTCAE v5.0 at 12 weeks. Planned start Aug 2022; status: withdrawn.
02
Drugs
ossm-001
03
Conditions
perianal fistula
Beyond the preview
Go deeper on NCT05407766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05407766.